Servier's $1.55 Billion Muscular Dystrophy Drug Fails Late-Stage Clinical Trial

French pharmaceutical company Servier announced Tuesday that its experimental drug sevasemten failed to meet primary and secondary endpoints in a late-stage clinical trial for Becker muscular dystrophy. The failure comes just five months after Servier committed $1.55 billion upfront to acquire the drug's original developer.[1][2][4]

The 18-month, placebo-controlled GRAND CANYON study evaluated 175 adults with the rare genetic disorder. Researchers measured patient progress using the North Star Ambulatory Assessment, a 17-item clinical rating scale that tracks motor function and mobility over time.[1][2]

The North Star Ambulatory Assessment evaluates a patient's ability to perform everyday movements, such as standing, walking, and climbing stairs. A decline in the score indicates disease progression, making it a critical benchmark for regulatory agencies evaluating new neuromuscular therapies.[1][2]

Patients receiving the daily oral tablet showed no statistically significant benefit over those taking a placebo. Servier confirmed that the drug maintained a favorable safety and tolerability profile, but the lack of efficacy marks a major setback for a condition that currently has no approved therapies.[2][3]

The outcome surprised industry analysts, as the drug had previously shown promise in earlier testing. "The results of the pivotal GRAND CANYON study are not aligned with certain findings observed in prior clinical studies, including the Phase 2 CANYON study," Servier stated in its release.[2]

A billion-dollar acquisition

Servier acquired sevasemten in June 2026 when it purchased the muscular dystrophy business of Colorado-based Edgewise Therapeutics. The deal was structured with a $1.55 billion upfront cash payment, handing Servier complete commercial and development control over the asset.[1][5][6]

The transaction included an additional $1.1 billion in potential regulatory and commercial milestone payments, bringing the total potential value to $2.65 billion. At the time, the acquisition was viewed as a bold move by the privately held French drugmaker to rapidly expand its rare neurology pipeline ahead of the pivotal data readout.[5][6]

Edgewise Therapeutics had advanced the drug through early trials before the acquisition, generating the Phase 2 data that attracted Servier's bid. Following the sale, Edgewise redirected its internal resources entirely toward its cardiovascular pipeline, including a mid-stage candidate for hypertrophic cardiomyopathy.[5][6]

In March 2026, Edgewise reported that patients taking sevasemten maintained stable ambulatory function for up to 3.5 years in an open-label extension study. That persistent stabilization stood in marked contrast to the functional decline typically expected from the natural history of Becker muscular dystrophy.[5]

Analysts had modeled a 55 percent probability of success for the drug based on that mechanistic and functional proof-of-concept. The promising early data convinced Servier to pay a premium for the asset before the pivotal trial was completed, accepting the risk of a late-stage failure.[5]

Servier President Olivier Laureau previously highlighted the drug as a cornerstone of the company's long-term strategy. He described the acquisition as a key step forward for Servier's 2030 ambition in neurology, emphasizing the urgent need for treatments in debilitating rare conditions.[1]

The mechanics of muscle protection

Becker muscular dystrophy is an inherited neuromuscular disorder caused by a variant in the gene that codes for dystrophin. This protein normally acts as a shock absorber, stabilizing muscle cell membranes and protecting them from mechanical injury during movement.[5]

Because patients with Becker produce a shorter, less functional form of dystrophin, their muscle fibers are highly vulnerable to damage from routine contractions. Over time, these damaged fibers weaken and die, leading to progressive muscle wasting and the buildup of scar tissue.[5]

Sevasemten was designed to intervene by targeting myosin, a protein critical for muscle contraction. The drug specifically inhibits the form of myosin found in fast-contracting muscle fibers, which generate the powerful forces needed for activities like running and climbing stairs.[5][6]

By limiting the force of these fast-twitch contractions, researchers hoped the drug would protect the fragile muscle tissue from repeated injury. The mechanism was intended to slow muscle breakdown and preserve ambulatory function without affecting the slower-contracting fibers used for endurance.[5][6]

Patient community response

The Muscular Dystrophy Association issued a statement Tuesday acknowledging the trial's failure while emphasizing the value of the collected data. The advocacy group noted that the 175-patient study was one of the largest ever conducted for this specific condition.[3]

"While we are disappointed that this trial did not demonstrate efficacy in adults with BMD, clinical research advances our understanding of the disease and informs the path forward," the organization stated.[3]

The association highlighted that the GRAND CANYON study has already contributed to advancements in outcome measures and trial design. They plan to host an educational webinar with Servier representatives to help patients and families understand the detailed findings once the data is fully analyzed.[3]

Becker muscular dystrophy affects approximately 12,000 individuals across the United States, five major European markets, and Japan. Because the disease progresses more slowly than the related Duchenne muscular dystrophy, designing trials that can detect a measurable difference in 18 months remains a persistent clinical challenge.[1][5]

Implications for Duchenne trials

The failure in Becker muscular dystrophy raises immediate questions about sevasemten's ongoing development for Duchenne muscular dystrophy. Servier is currently running a separate Phase 2 trial evaluating the drug in patients with Duchenne, a more severe form of the disease.[1][5]

Duchenne typically leads to a loss of walking ability in early adolescence and carries a median life expectancy of roughly 30 years. While some targeted therapies exist for specific genetic mutations in Duchenne, there is still a massive unmet need for treatments that can preserve muscle function across the broader patient population.[5][6]

Duchenne muscular dystrophy is characterized by a complete absence of functional dystrophin, rather than the shortened version seen in Becker. Because the underlying mechanical vulnerability is similar, researchers had hoped that protecting fast-twitch muscle fibers would benefit both patient populations.[5][6]

Servier has not yet indicated whether the GRAND CANYON results will alter the design or continuation of the Duchenne trials. The company stated it is conducting a comprehensive analysis of the Becker dataset alongside prior clinical data to better characterize the findings.[1][2]

The company plans to present the full results of the GRAND CANYON study at a future medical conference. Until then, researchers will be looking closely at the secondary endpoints and biomarker data to understand why the functional improvements seen in Phase 2 did not translate to the larger cohort.[2]

The broader development landscape

The setback underscores the high risks associated with developing drugs for rare neuromuscular disorders. Pharmaceutical companies frequently rely on early-stage functional data and biomarkers to justify massive investments, but Phase 3 trials remain a formidable hurdle.[4][6]

For Edgewise Therapeutics, the June acquisition provided a substantial infusion of non-dilutive capital before the trial results were known. The company's decision to sell the asset shifted the clinical risk entirely to Servier while securing funding for its remaining pipeline.[5][6]

Servier remains a major player in the rare disease space, having executed multiple billion-dollar acquisitions over the past two years to build its portfolio. The company reiterated its commitment to driving rare neurology innovations forward despite the sevasemten failure.[1][2]

The next steps for the Becker muscular dystrophy community will depend on the insights extracted from the trial data. Researchers will use the 18-month natural history and placebo data to refine the North Star Ambulatory Assessment for future drug candidates.[2][3]

The trial's completion provides a robust dataset that will serve as a baseline for the next generation of therapies. The exact timeline for Servier's full data presentation has not been announced, leaving patients and clinicians waiting for the final scientific post-mortem.[2]